Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

REGN vs AMGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AMGN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

AMGN Overall Winner 6-Pillar Tally: REGN 3 – 3 AMGN Matrix Metrics: REGN 5 – 5 AMGN

As of Nov 19, 2026, Amgen Inc (AMGN) is the stronger overall head-to-head candidate over Regeneron Pharmaceuticals Inc (REGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas AMGN carries 48.4/100 (HOLD) at $438.82 (17.5x Forward P/E, 34.1% operating margin).

  • Growth vs. Quality Trade-Off: AMGN earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. REGN 42.6/100 HOLD) and 0.47β · 26% Vol risk profile, whereas REGN leads top-line expansion (+36.3% YoY revenue growth, 1.15x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About REGN vs AMGN
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
TTM Revenue $16.9B
Forward P/E 14.9x
Beta / 30D Vol 0.32β · 55% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97
AMGN NASDAQ Head-to-Head Winner
Amgen Inc
Biological Products, (No Disgnostic Substances)
$438.82
-1.14% 1D
Market Cap $240.1B
TTM Revenue $38.9B
Forward P/E 17.5x
Beta / 30D Vol 0.47β · 26% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 68.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.8 · SMA20: $458.53 · SMA50: $429.28

6-Pillar Scorecard Institutional Category Breakdown (REGN 3 – 3 AMGN)

Columns: Metric · REGN · AMGN
1. Valuation Multiples REGN
Forward P/E 14.9x 17.5x
Trailing P/E 20.9x 25.7x
PEG Ratio 1.15x 2.76x
EV / Revenue 5.7x 7.2x
2. Growth & Scale REGN
Revenue Growth (YoY) +36.3% +8.5%
Earnings Growth (YoY) +35.5% +19.4%
TTM Revenue (USD) $16.9B $38.9B
Market Cap $97.8B $240.1B
3. Profitability & Quality AMGN
Gross Margin 46.7% 72.5%
Operating Margin 30.4% 34.1%
Net Profit Margin 28.5% 24.1%
Return on Equity (ROE) 14.9% 78.3%
4. Balance Sheet & Cash Flow AMGN
Cash Generation (TTM) $3.63B $9.58B
Cash Flow Margin 21.5% 24.6%
Net Cash / Leverage $952M Net Cash $40.8B Net Debt (3.76x D/E)
Dividend Yield 0.39% 2.17%
5. Options & Positioning REGN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 35.5% (6th %ile) 33.8% (6th %ile)
Put/Call OI Skew 0.47x (Call-Skewed) 0.59x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat AMGN
OpEx & R&D Intensity 16.3% of Rev ($2.75B) 38.4% of Rev ($14.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: REGN (5) vs AMGN (5)
Institutional Metric REGN AMGN Criterion Row Edge
Market Capitalization
Scale
$97.8B $240.1B Larger Scale AMGN
Trailing P/E Ratio
Valuation
20.9x 25.7x Lower Multiple REGN
Forward P/E Ratio
Valuation
14.9x 17.5x Lower Multiple REGN
Revenue Growth (YoY)
Growth
+36.3% +8.5% Higher Growth REGN
Operating Margin (TTM)
Profitability
30.4% 34.1% Higher Margin AMGN
Net Profit Margin
Profitability
28.5% 24.1% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
14.9% 78.3% Higher ROE AMGN
52-Week Range Position
Momentum
83% ($592–$992) 74% ($312–$484) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.32β · 55% Vol 0.47β · 26% Vol Lower Realized Risk AMGN
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite AMGN
Trailing 12M Revenue (USD)
Operating Scale
$16.9B $38.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 72.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.15x PEG · 5.7x EV/Rev 2.76x PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.63B ($952M Net Cash) $9.58B ($40.8B Net Debt (3.76x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +14.5 pp
REGN: +14.61% · AMGN: +0.11%
3M Horizon REGN +10.83 pp
REGN: +10.71% · AMGN: -0.12%
6M Horizon REGN +13.64 pp
REGN: +43.69% · AMGN: +30.05%
1Y Horizon AMGN +0.27 pp
REGN: +27.3% · AMGN: +27.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period REGN Revenue AMGN Revenue REGN Op. Margin AMGN Op. Margin Margin Leader
FY2018 $5.15B $23.8B 49.3% 43.2% REGN
FY2019 $6.56B $23.4B 33.7% 41.4% AMGN
FY2020 $8.50B $25.4B 42.1% 35.9% REGN
FY2021 $16.1B $26.0B 55.7% 29.4% REGN
FY2022 $12.2B $26.3B 38.9% 36.3% REGN
FY2023 $13.1B $28.2B 30.9% 28.0% REGN
FY2024 $14.2B $33.4B 28.1% 21.7% REGN
FY2025 $14.3B $36.8B 24.9% 24.7% REGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
REGN CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV 35.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMGN CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV 33.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.59x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AMGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $952.40 · IV 33.5%

REGN vs. AMGN: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of REGN ($95,240) vs. AMGN ($46,232) against risk-defined 5-day vertical and put-wall option structures.

REGN Spot $952.40 · IV 33.5%
REGN Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
AMGN Spot $462.32 · IV 28.0%
AMGN Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $460 / $480 Bull Call Spread

Buy 1x $460C · Sell 1x $480C · 31d

Net Entry $980 Debit
T+5d @ +5% Move +$431 (+44%)
Max Risk / Buffer $980 Capped
5d Edge & Liquidity 0.8x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $440 / $420 Bull Put Spread

Sell 1x $440P · Buy 1x $420P · 31d

Net Entry $373 Credit
Max Credit / Yield +$373 (+22.9% RoM)
Max Risk / Buffer -5.6% Cushion ($1,627 Mgn)
5d Edge & Liquidity 75% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published
AMGN Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $240.1B market capitalization and 34.1% operating margin.
OpEx & R&D Reinvestment 38.4% of Rev ($14.9B)
90D Engineering Disclosures 0 Published

Investor FAQ REGN vs AMGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Amgen Inc (AMGN) is the stronger overall head-to-head candidate over Regeneron Pharmaceuticals Inc (REGN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas AMGN carries 48.4/100 (HOLD) at $438.82 (17.5x Forward P/E, 34.1% operating margin). Growth vs. Quality Trade-Off: AMGN earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. REGN 42.6/100 HOLD) and 0.47β · 26% Vol risk profile, whereas REGN leads top-line expansion (+36.3% YoY revenue growth, 1.15x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with AMGN at +8.5% YoY revenue growth and +19.4% YoY earnings growth on $38.9B TTM revenue (72.5% gross margin, 34.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), REGN cumulative revenue shifted +178.4% while AMGN shifted +54.7%. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus 38.4% of Rev ($14.9B) (0 disclosures) for AMGN.

REGN screens cheaper on headline valuation multiples. REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin), whereas AMGN trades at 17.5x Forward P/E, 25.7x Trailing P/E, 2.76x PEG, and 7.2x EV/Revenue (24.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus AMGN (78.3% ROE) capital efficiency.

In options market volatility and institutional positioning, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk). By comparison, AMGN carries 33.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.59x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.47β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.